Mr. Wiggans co-founded Dermira in 2010 and served as the Chief Executive Officer and Chairman of the board of directors until its acquisition by Eli Lilly in February 2020. He brings more than 30 years of experience in specialty pharma and 18 years of experience in dermatology. Prior to founding Dermira, he served as Chairman of the board of directors and Chief Executive Officer of Peplin, Inc., until Peplin’s acquisition by LEO Pharma A/S in 2009. Previously, he served as Chairman of the board of directors and Chief Executive Officer of Connetics Corporation until Connetics was acquired by Stiefel Laboratories, Inc., in 2006. Prior to Connetics, he served as President and Chief Operating Officer of CytoTherapeutics Inc., and in various management positions at Ares-Serono S.A., including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. He began his career with Eli Lilly and Company.

Mr. Wiggans has served on the boards of various industry organizations, educational institutions, and private and public companies, including service on the boards of directors of Onyx Pharmaceuticals, Inc. (until its acquisition by Amgen in 2013), Sangamo Biosciences, Inc., and Somaxon Pharmaceuticals, Inc.

In addition, Mr. Wiggans is a member of the board of directors of Biotechnology Innovation Organization, a nonprofit educational organization, and is a member of the board of trustees of the University of Kansas Endowment Association. He holds a BS in pharmacy from the University of Kansas and an MBA from Southern Methodist University.